Top Ten most popular articles on Pharmafile.com this week
pharmafile | March 13, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Chinese Coronavirus, Coronavirus Wuhan, HIV, HIV/AIDS, UK Coronavirus, coronavirus
HIV treatment featured heavily in the news this week, as Uganda is preparing to enter the final stages of developing a new HIV treatment to reduce stigma and discrimination of those living with the disease, while Adam Castillejo has become the second man to be cured of HIV, after being free of the virus for more than 30 months.
In coronavrius news, China has moved to authorise Roche’s Actemra (tocilizumab) as a treatment for severe complications from contracting the COVID-19 coronavirus in a bid to contain the ongoing national and global outbreak of the virus.
10. ACC.20 cancelled due to coronavirus fears
The American College of Cardiology has cancelled its upcoming ACC.20 event with the World Congress of Cardiology due to concerns about the COVID-19 outbreak.
9. Uganda finalising clinical trials on new injectable HIV drug
Uganda is preparing to enter the final stages of developing a new HIV treatment to reduce stigma and discrimination of those living with the disease.
8. The need for evolution in pharmacovigilance
Pharmacovigilance is a critical function in ensuring public health, but is our current system built to tackle the challenges of evolving science and political upheaval in the modern world? Matt Fellows investigates.
7. A man from London becomes second person to be cured of HIV
Adam Castillejo is the second man to be cured of HIV, after being free of the virus for more than 30 months.
6. NICE shoots down Dupixent for severe asthma
NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 inhibitor Dupixent (dupilumab) in the treatment of severe asthma.
5. Keytruda rejected for NHS use for bladder cancer, will be removed from the Cancer Drugs Fund
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) has been knocked back by NICE for use on the NHS as a treatment for locally advanced or metastatic urothelial carcinoma in patients who have previously undergone platinum-containing chemotherapy.
4. Biogen and Takeda forced to send employees home as coronavirus hits Massachusetts
Big pharma has been hit by the coronavirus (COVID-19) outbreak right on its doorstep, as two of the biggest names based in the Boston and Cambridge life sciences cluster – Biogen and Takeda – revealed that their workforce had been compromised.
3. China approves Roche’s Actemra to fight severe complications stemming from coronavirus
China has moved to authorise Roche’s Actemra (tocilizumab) as a treatment for severe complications from contracting the COVID-19 coronavirus in a bid to contain the ongoing national and global outbreak of the virus.
2. UK Government outlines emergency measures to tackle coronavirus
The British Government has outlined its emergency legislation to tackle coronavirus in which people could leave work to become volunteers to care for sufferers of the disease.
1. Indian regulators approve first drug for patients with NASH
The Drug Controller General of India (DCGI) has approved the marketing application for Zydus Cadila’s saroglitazar to treat patients with non-cirrhoitc non-alcoholic steatohepatitis (NASH).
Related Content
Gilead and Merck share data from phase 2 trial of HIV treatment
Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced …
ViiV Healthcare shares interim data from phase 3 trial for injectable HIV treatment
ViiV Healthcare has announced results from an interim analysis of the phase 3 LATITUDE trial, …
China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved …
